Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK-1830
- Development stage
- Phase 2
- Lead developer
- Asahi Kasei Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AK-1830 is a potent, orally available small molecule inhibitor of tropomyosin receptor kinase A (TrkA), also known as the nerve growth factor receptor. It is being developed primarily for the treatment of pain associated with osteoarthritis and chronic low back pain. The drug acts as a TrkA antagonist, blocking NGF-mediated signaling to provide analgesic and anti-inflammatory effects. Originally developed by Array BioPharma, now a subsidiary of Pfizer, it is currently under development by Asahi Kasei Pharma in Japan. Clinical trials have reached Phase II for both osteoarthritis and chronic low back pain[1][2][3][7].
- Other names
- ARRY-954ARRY954ARRY 954AK 1830AK1830AK-1830
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on AK-1830.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK-1830.